Produit
AGENTS IA
APPLICATIONS DE L'IA
AUTRES
Solutions
SECTEURS D'ACTIVITÉ
Tarification
Ressources
EXPLORER
ENGAGER
ASSISTANCE ET SERVICES
À propos
Plateforme PatSnap Eureka
Mandataires en propriété intellectuelle
Agents pour l'ingénierie
Agents pour les sciences de la vie
Agents pour matériaux
Analytique
Intelligence IPSynapse
Renseignement biopharmaceutiqueBiographie
Recherche et analyse de séquences biologiquesChimique
Recherche et analyse de structures chimiquesPlateforme ouverte
Services professionnels
Témoignages clients
Newsroom
Blog
Rapport mondial sur l'innovation
Glossaire
Webinaires et formations
Frontière
Communauté d'utilisateurs
Confiance et sécurité
PatentBench
LLM
Centre d'aide
Carrières
Accès à plus de 2 000 000 000 points de données structurées dans les domaines des brevets, des sciences, des litiges et des technologies.
Innovez 75 % plus vite à un coût réduit de 25 %.
Cloud ou sur site pour une confidentialité et un contrôle maximaux
Reconnu par plus de 18 000 innovateurs à travers le monde
Pour l'utiliser, cliquez sur le bouton de vérification dans l'e-mail que nous avons envoyé à [email protected].
Cela contribue à sécuriser votre compte.
Vous devriez le recevoir sous peu. N'oubliez pas de vérifier votre dossier spam.
Unlock professional features and history
Already have an account? Log In
To start using PatSnap Eureka, click the verification button in the email we sent to .
This helps keep your account secure.
Haven't received it? Check your spam folder.
Série soigneusement sélectionnée offrant des informations précieuses aux professionnels de l'innovation.
Article | Rapport BMS's Cobenfy (xanomeline-trospium) targets Alzheimer's disease psychosis in ADEPT Phase III, with H2 2026 readout set to challenge pimavanserin's contested hold on the market.
Article | Rapport How AI is transforming the way materials engineers search for and evaluate substitutes during critical raw material supply disruptions. Explore the tools and frameworks reshaping industrial resilience.
Article | Rapport A 2026 landscape of in-memory analog computing: RRAM, PCM, flash-based neural memory, and NV-CAM patents mapped across key assignees and emerging directions.
Article | Rapport Imetelstat Phase III data in low-risk MDS: transfusion independence outcomes, Geron/J&J trial results, and competitive positioning against luspatercept.
Article | Rapport How engineers manage EMC between high-power wireless charging systems and vehicle electronics — standards, shielding strategies, and IP research tools explained.
Article | Rapport A 2026 landscape of epigenome editing technology: CRISPR/dCas9 platforms, key innovators, patent trends, and therapeutic applications — without altering DNA sequence.
Article | Rapport How AI-assisted computer vision improves dimensional measurement accuracy in high-speed automated assembly lines — technology landscape, methods, and industry implications.
Article | Rapport Pfizer's marstacimab anti-TFPI antibody enters Phase III for hemophilia A and B. How does it stack up against emicizumab and fitusiran in the non-factor race?
Article | Rapport A 2026 landscape of collaborative robot safety technology: collision detection, SSM, sensor fusion, cybersecurity co-assurance, and emerging IP signals across 15+ countries.
Article | Rapport A 2026 patent and literature landscape of molten salt reactor fuel processing: fluoride/chloride salt formulation, pyrochemical reprocessing, and spent LWR fuel conversion.
Article | Rapport Novo Nordisk's Mim8 bispecific antibody targets FIXa and FX to challenge Hemlibra in hemophilia A. Explore the clinical, IP, and competitive landscape ahead of the FDA decision.
Article | Rapport No patent or literature data was available to support this article. Learn how to expand your search for deep space radiation qualification research using PatSnap Eureka.
Article | Rapport How cerebral organoid maturation is evolving in 2026: vascularization breakthroughs, bioreactor engineering, epigenetic benchmarking, and the IP landscape mapped.
Article | Rapport Faricimab (Vabysmo) expands into RVO and DME with treat-and-extend dosing up to 16 weeks. Analyse Roche's dual VEGF/Ang-2 IP strategy and competitive durability data.
Article | Rapport How AI transforms competitive benchmarking workflows for R&D teams evaluating new technology platforms — from patent landscape analysis to decision support.